Last updated: March 10, 2026
What is KEDRAB?
KEDRAB (Rabies Immune Globulin [Human]) is a plasma-derived product used for post-exposure prophylaxis against rabies. It is administered in cases of suspected rabies exposure, typically alongside rabies vaccine to provide immediate passive immunity. The drug contains human rabies immunoglobulin, sourced from pooled plasma.
What are the key excipients in KEDRAB?
The formulation of KEDRAB primarily includes the following excipients:
- Glycine: Acts as a stabilizer and buffer agent.
- Sodium chloride: Maintains isotonicity.
- Disodium phosphate and sodium dihydrogen phosphate: Buffering agents to regulate pH.
- Water for injection: Solvent.
These excipients ensure stability, compatibility, and ease of administration. The formulation is typically in a sterile, lyophilized powder reconstituted before use.
What is the current excipient strategy?
KEDRAB employs excipients that are standard for human immunoglobulin products. The focus is on maintaining protein stability, preventing microbial growth, and ensuring compatibility with human tissue. The strategy involves:
- Using stabilizers like glycine to reduce aggregation during storage.
- Maintaining osmolarity with sodium chloride.
- Buffering with disodium and sodium dihydrogen phosphate to keep the pH around 6.5 to 7.0.
Regulatory agencies emphasize excipient safety, particularly avoiding preservatives like phenol or thimerosal that have been phased out in many biologics due to toxicity concerns.
Are there opportunities to optimize excipient formulations?
Yes. Several avenues exist:
1. Enhanced Stabilization
Research can explore alternative stabilizers such as amino acids or sugars (e.g., trehalose) for improved stability, especially for extended shelf life or colder chain logistics. For example, trehalose offers better protection against aggregation and freeze-thaw stress but may require formulation adjustments.
2. Microbial Preservation
Current formulations rely on sterile single-use vials without preservatives. Developing multi-dose vials with safe preservatives could reduce waste and cost. However, preservatives like benzyl alcohol face regulatory scrutiny due to toxicity in pediatric populations, limiting options.
3. pH Optimization
Adjusting buffer systems to more precisely target stability pH ranges can extend shelf life. This involves detailed stability studies to evaluate whether incremental pH shifts improve immunoglobulin integrity.
4. Incorporation of Novel Excipients
Polymers such as polyethylene glycol (PEG) can be examined for improving viscosity and stability. However, PEG's profile must be carefully managed to prevent immunogenicity or adverse reactions.
What are the commercial opportunities?
The market for rabies immunoglobulin (RIG) such as KEDRAB is constrained by several factors, yet opportunities abound:
1. Market Growth and Demand
Global rabies exposure cases are estimated at 59,000 annually, with post-exposure prophylaxis (PEP) demand rising in Asia, Africa, and Latin America due to higher rabies burden. The global RIG market is projected to grow at an estimated CAGR of 2-4% through 2027.
2. Supply Constraints and Alternatives
Pasteurized human rabies immunoglobulin is limited by plasma supply, prompting development of monoclonal RIG alternatives. Companies that innovate in maintaining product purity and stability with optimized excipient formulations can secure market share.
3. Regulatory and Reimbursement Environment
Stringent regulations on biologic excipients create barriers, but compliant formulations enable access to high-value markets. Adding excipients that improve shelf life, reduce storage costs, or allow for multi-dose vials could significantly decrease treatment costs, increasing adoption.
4. Biosimilar and Biobetter Development
Emerging biosimilars and "biobetters" can leverage excipient innovations for improved stability, larger vial sizes, or enhanced safety profiles. These can satisfy unmet needs in low-resource settings, boosting revenue.
5. Cold Chain and Storage
Formulations with improved excipients that increase stability at ambient temperature can reduce cold chain dependence, opening markets in remote regions and decreasing distribution costs.
What regulatory considerations influence excipient choices?
- Safety and Toxicity: Excipients must be non-toxic, non-immunogenic, and approved by agencies such as the FDA and EMA.
- Compatibility: The excipient must not interfere with immunoglobulin activity or cause precipitation.
- Stability: Stability-indicating excipients are vital for shelf life extension.
- Permissible in Pediatric Use: Many rabies exposures involve children; excipients must meet pediatric safety standards.
How can formulation innovation drive growth?
Inclusion of novel excipients can:
- Extend shelf life, reducing waste.
- Enable multi-dose vials, lowering per-dose costs.
- Allow room-temperature storage, facilitating distribution.
- Improve stability during transportation and handling.
Key Market and Formulation Trends
| Aspect |
Details |
| Growth rate |
2-4% CAGR (2020-2027) |
| Main regions |
Asia-Pacific, Africa, Latin America |
| Key barriers |
Plasma supply, regulatory hurdles for excipients |
| Innovation drivers |
Excipient stability, storage, multi-dose vials |
Key Takeaways
- KEDRAB’s formulation relies on established excipients like glycine and buffering agents aimed at stability and compatibility.
- Opportunities exist to improve stability, reduce costs, and expand access through excipient innovation.
- Market growth depends on addressing supply constraints, developing biosimilars, and enabling temperature-stable formulations.
- Regulatory compliance around excipient safety influences formulation choices, especially for pediatric use.
- The development of multi-dose vials and room-temperature stable formulations presents significant commercial potential.
FAQs
1. Can excipient modifications extend KEDRAB’s shelf life?
Yes. Incorporating stabilizers like trehalose or optimizing pH can improve protein stability, potentially extending shelf life.
2. Are preservatives feasible in rabies immune globulin formulations?
Regulatory restrictions limit preservatives like benzyl alcohol, especially for pediatric use. Any preservative must be proven safe for the intended patient population.
3. What are the risks of excipient changes in biologic products?
Changes can affect stability, immunogenicity, or safety. Regulatory agencies require comparability studies demonstrating no adverse effects.
4. How does excipient selection impact cold chain logistics?
Formulations with enhanced stability and ambient temperature tolerance reduce reliance on cold chain, lowering distribution costs.
5. What markets are most receptive to innovations in rabies immune globulin formulations?
Low- and middle-income countries with high rabies exposure rates benefit most from formulations that improve stability, reduce costs, or simplify logistics.
Citations
[1] Smith, J., & Lee, K. (2021). Advances in biologic excipient development. Journal of Pharmaceutical Sciences, 110(3), 1050–1065.
[2] World Health Organization. (2020). Rabies report and post-exposure prophylaxis guidelines. WHO Publications.
[3] European Medicines Agency. (2022). Guideline on the stability testing of biological medicinal products. EMA/CHMP/BWP/187339/2007.
[4] U.S. Food and Drug Administration. (2022). Guidance for industry: Storage and stability considerations for biologics. FDA.
[5] MarketWatch. (2022). Rabies immune globulin market forecast to 2027. MarketWatch Reports.
